このコンテンツを視聴するには最新バージョンの Adobe Flash Player を利用していることが必要です。
: 2016-07-20- Evec has started offering several contract services.
contract service - : 2014-07-17
- Our anti-MPV Abs, EV046120 and EV046135, have high neutralization activities not only for MPV but also for RSV.
- : 2014-06-20
- Monoclonal Abs that we have generated are those for Cytomegalovirus, Clostridium difficile, RS virus, human Metapneumovirus (hMPV) and high mobility group box 1 (HMGB1). We are seeking for pharmaceutical companies who could develop these Abs toward pharmaceuticals. Please contact info@evec.jp.
please click here - : 2011-09-05
- Evec signed the contract with Astellas Pharma Inc. , licensing one antibody for commercial development.
Astellas Pharma Inc. - : 2010-01-22
- Kenzo Takada, MD, PhD received the Hokkaido Science and Technology Award.
- : 2008-09-30
- Evec signed the contract with Boehringer Ingelheim GmbH (Germany), licensing one kind of antibody for commercial development.
Evec develops fully human antibodies with high affinity and less side effect, and provides them to companies seeking for antibody medicine, and jointly pursue further antibody development with allied partners.
Evec devised the technique, independent from the costly Western patents, to develop fully human antibodies from blood B lymphocytes, responsible for humoral immunity in human body.
